The Patent Finder

SRX Cardio, LLC

11 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Feb 2034
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 4, 2026
    The maintenance fee for Composition and Methods of Use of Small Molecules as Binding Ligands for the Modulation of Proprotein Convertase Subtilisin/Kexin Type 9(PCSK9) Protein Activity (US 10,307,433) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
  • 1 fee due Apr 3, 2027
    The maintenance fee for Method to Treat Lipid Dysregulation by Modulation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein Activity with Small Molecule Ligands (US 11,771,710) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
  • 2 fees due Aug 6 to 25, 2027 · next Aug 6
  • 1 fee due Sep 12, 2027
    The maintenance fee for Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators and Their Use (US 11,925,637) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
  • 2 fees due Oct 2, 2027

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,287,317Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,307,433Composition and Methods of Use of Small Molecules as Binding Ligands for the Modulation of Proprotein Convertase Subtilisin/Kexin Type 9(PCSK9) Protein Activity
In force
 · High confidence
In forceHigh confidence
US 10,688,114Composition and Methods of Use of Small Molecules as Binding Ligands for the Modulation of Proprotein Convertase Subtilisin/Kexin Type 9(PCSK9) Protein Activity
In force
 · High confidence
In forceHigh confidence
US 11,771,710Method to Treat Lipid Dysregulation by Modulation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein Activity with Small Molecule Ligands
In force
 · High confidence
In forceHigh confidence
US 10,568,882Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators and Their Use
In force
 · High confidence
In forceHigh confidence
US 10,821,106Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate PCSK9 Protein Activity
In force
 · High confidence
In forceHigh confidence
US 11,925,637Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators and Their Use
In force
 · Medium confidence
In forceMedium confidence
US 11,944,619Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate PCSK9 Protein Activity
In force
 · High confidence
In forceHigh confidence
US 11,891,369Compounds for Binding Proprotein Convertase Subtilisin/Kexin Type 9
In force
 · High confidence
In forceHigh confidence
US 11,945,782Composition and Methods of Use of Tetrahydroisoquinoline Small Molecules to Bind and Modulate PCSK9 Protein Activity
In force
 · High confidence
In forceHigh confidence
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited